Fate Therapeutics Inc SEC filings FATE
Fate Therapeutics Inc has 855 filings in SEC EDGAR's recent list, going back to May 2, 2008. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, agreement ended). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 25, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2024 | — |
| EFFECT | Filing | Nov 27, 2023 | — |
| CORRESP | Letter to the SEC | Nov 21, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2023 | — |
| D | Filing | Jul 6, 2020 | — |
| D | Filing | Apr 21, 2020 | — |
| CT ORDER | Filing | Feb 27, 2019 | — |
| CT ORDER | Filing | Sep 12, 2018 | — |
| CT ORDER | Filing | Jul 19, 2018 | — |
| EFFECT | Filing | May 14, 2018 | — |
| CORRESP | Letter to the SEC | May 11, 2018 | — |
| UPLOAD | Letter from the SEC | May 11, 2018 | — |
| CT ORDER | Filing | Mar 19, 2018 | — |
| EFFECT | Filing | Aug 25, 2017 | — |
| CORRESP | Letter to the SEC | Aug 23, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2017 | — |
| EFFECT | Filing | Jan 24, 2017 | — |
| CORRESP | Letter to the SEC | Jan 20, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 18, 2017 | — |
| D | Filing | Dec 8, 2016 | — |
| EFFECT | Filing | Sep 28, 2016 | — |
| CORRESP | Letter to the SEC | Sep 26, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 22, 2016 | — |
| D | Filing | Aug 19, 2016 | — |
| CT ORDER | Filing | Jul 8, 2016 | — |
| CT ORDER | Filing | Nov 12, 2015 | — |
| CT ORDER | Filing | Jun 18, 2015 | — |
| D | Filing | May 18, 2015 | — |
| EFFECT | Filing | Oct 15, 2014 | — |
| CT ORDER | Filing | Oct 1, 2013 | — |
| EFFECT | Filing | Sep 30, 2013 | — |
| CORRESP | Letter to the SEC | Sep 30, 2013 | — |
| CORRESP | Letter to the SEC | Sep 30, 2013 | — |
| CERTNAS | Auto-generated paper document | Sep 18, 2013 | — |
| 8-A12B | Form 8-a12b | Sep 17, 2013 | — |
| CORRESP | Letter to the SEC | Sep 16, 2013 | — |
| CORRESP | Letter to the SEC | Sep 16, 2013 | — |
| CORRESP | Letter to the SEC | Aug 29, 2013 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2013 | — |
| CORRESP | Letter to the SEC | Aug 22, 2013 | — |
| CORRESP | Letter to the SEC | Aug 13, 2013 | — |
| D | Filing | Aug 13, 2013 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2013 | — |
| DRS/A | Filing | Jul 29, 2013 | — |
| DRSLTR | Filing | Jul 26, 2013 | — |
| UPLOAD | Letter from the SEC | Jul 17, 2013 | — |
| DRSLTR | Filing | Jun 20, 2013 | — |
| DRS | Filing | Jun 20, 2013 | — |
| D | Filing | Aug 21, 2012 | — |
| D | Filing | Apr 20, 2011 | — |
| D/A | Filing | Apr 20, 2011 | — |
| D/A | Filing | Dec 24, 2009 | — |
| D | Filing | Nov 23, 2009 | — |
| REGDEX | Auto-generated paper document | May 2, 2008 | — |
| REGDEX | Auto-generated paper document | May 2, 2008 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FATE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434316
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.